 SALT LAKE CITY, March 11, 2021 PRNewswire -- Lipocine Inc. NASDAQ: LPCN, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the fourth quarter and year ended December 31, 2020, and provided a corporate update. Lipocine had a number of important accomplishments in 2020, most notably the U.S. Food and Drug Administration FDA decision to grant tentative approval to TLANDO, the Companys oral testosterone product for testosterone replacement therapy TRT in adult males with hypogonadism. 